Form 4: Edwards Lifesciences Executive Equity Grant Disclosure

SVP and Corporate Controller Andrew M. Dahl received restricted stock units and stock options as part of the company's long-term incentive program.

Summary

• Andrew M. Dahl, SVP and Corporate Controller of Edwards Lifesciences, was granted 3,985 and 3,020 restricted stock units (RSUs) on May 7, 2026.
• The reporting person was also granted 6,745 employee stock options with an exercise price of $82.76.
• A total of 289 shares were withheld on May 8, 2026, at a price of $82.76 to satisfy tax obligations.
• Following these transactions, the reporting person holds 15,901.6214 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which carries a neutral sentiment for investors.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention of key financial leadership through multi-year vesting schedules.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though standard for corporate compensation programs.

Risks

• Market price volatility affecting the ultimate value of granted stock options and RSUs.
• Dependence on future company performance to meet vesting requirements.

Future Outlook

The equity grants are subject to a four-year vesting schedule, indicating management's focus on long-term retention and performance.

Management Comments

• The grants were issued under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program.

Industry Context

StockSavvy.ai notes that equity grants to senior financial officers are standard practice in the medical device industry to ensure leadership stability and alignment with long-term strategic goals.

Comparison to Industry Standards

• The use of four-year vesting schedules for RSUs and options is consistent with standard executive compensation practices at large-cap medical technology firms like Medtronic and Boston Scientific.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensatory grants.

Next Steps

• Vesting of equity grants to commence on May 7, 2027.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Equity Compensation, Stock Options, Restricted Stock Units